Fruquintinib Patent Expiration

Fruquintinib is Used for the treatment of metastatic colorectal cancer that is resistant to multiple chemotherapies and targeted therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Fruzaqla on Nov 8, 2023.


Fruquintinib Patents

Given below is the list of patents protecting Fruquintinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Fruzaqla US10519142 Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide Sep 07, 2035 Takeda Pharms Usa
Fruzaqla US11046674 Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide Sep 07, 2035 Takeda Pharms Usa
Fruzaqla US7829574 Substituted quinazoline compounds and their use in treating angiogenesis-related diseases May 09, 2028 Takeda Pharms Usa
Fruzaqla US8212033 Use of substituted quinazoline compounds in treating angiogenesis-related diseases May 09, 2028 Takeda Pharms Usa


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳